$TAK

AI Analysis

Generated on May 11, 2026

AI Score
64/ 100
Hold$TAK

Takeda Pharmaceutical

$TAKNYSEHealthcareLarge-Cap

Takeda develops and delivers medicines in gastroenterology, rare diseases, plasma therapies, oncology, and neuroscience.

Market Cap
$48.0B
Revenue (TTM)
$30.5B
+3.0%
Net Income (TTM)
$2.5B
+5.0%
EPS (TTM)
$1.60
P/E Ratio
20.0
Dividend Yield
4.5%
52-Week Range
$12-$18
Beta
0.52
Dimension Scores
Fundamental
66
Technical
58
Sentiment
62
Risk / Reward
70
Momentum
52
FundTechSentRiskMome
Financial Health
Profitability
71moderate
Growth
55moderate
Liquidity
78strong
Solvency
68strong
Efficiency
64strong

Valuation, technical analysis, investment thesis, risk assessment and more for $TAK

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.